* For a separate FACTBOX on other vaccines, click
(Adds Switzerland supply deal in table 4)
Oct 16(Reuters) - AstraZeneca's experimental COVID-19 vaccine is one of
the most advanced candidates in the race against the novel coronavirus.
The British drugmaker has signed several supply and manufacturing deals with
companies and governments around the world as it gets closer to reporting early
results of a late-stage clinical trial.
Developed by the University of Oxford and licensed to AstraZeneca in April, the
vaccine is expected to be one of the first from big pharma to secure regulatory
approval, along with Pfizer and BioNTech's candidate.
Although drugmakers and researchers are also working on various treatments,
vaccines are at the heart of the long-term fight to stop the virus, which has killed
more than a million people, infected more than 38 million and crippled the global
economy.
Below are the main details of the British vaccine.
TYPE
* Called AZD1222 or ChAdOx1 nCoV-19, the vaccine is a recombinant viral vector
vaccine.
* It uses a weakened version of a chimpanzee common cold virus that encodes
instructions for making proteins from the novel coronavirus to generate an immune
response and prevent infection.
DOSAGE AND PROTECTION DURATION
* AstraZeneca and Oxford University have said a two-dose regimen showed greater
promise, while a single-dose injection is also being tested in trials.
* The vaccine is likely to provide protection for about a year, CEO Pascal Soriot
said
in June.
EXPECTED COST/PRICING
* In the first indication of pricing, Italy's health ministry said in June an
AZD1222
vaccine would cost about 2.5 euros ($2.8) per dose in Europe.
* AstraZeneca said in July it will be able to manufacture the vaccine at a few
dollars
per dose.
* Pricing in Latin America, while still not final, is not expected to exceed $4
per
dose, AstraZeneca's Mexico head said in August.
* The Serum Institute of India said in August it would price the vaccine at $3
per dose
for India and other emerging economies.
* Costs in other regions have not been disclosed so far.
* AstraZeneca has said it would not profit from the vaccine during the pandemic,
but a
report from the Financial Times in October showed the company can declare when it
considers the pandemic to have ended in its deals for the vaccine.
TESTING
* AstraZeneca had to pause global trials on Sept. 6 after an unexplained illness
in a
participant.
* Most trials have since resumed, although the United States has widened its
investigation. President Donald Trump is pushing for a vaccine to be fast-tracked
before November's presidential elections.
* AstraZeneca's CEO said in July that good data had come in on the vaccine, after
early-stage trials showed it was safe and produced an immune response.
GLOBAL TRIALS
(In alphabetical order of geographies)
REGION STAGE OF STATUS VOLUNTEERS EXPECTED COMPLETION
DEVELOPMENT
Brazil Phase III Ongoing, 5,000 estimated, Sept. 2021 (bit.ly/2GAeB4K)
restarted with participants
after pause aged 18 years and
in older
September
India Phase II/III Ongoing, 1,600 estimated, In seven months
restarted with participants from August (bit.ly/3nAwXTC)
after pause aged 18 years and
in older
September
Japan Phase I/II Ongoing, 12 estimated, with Sept. 2021 (bit.ly/3nAnImj)
restarted participants aged
after pause 18 years and older
in
September
Russia Phase III On hold, 100 estimated, with March 2021 (bit.ly/36NKpxr)
paused in participants aged
September 18 years and older
South Africa Phase I/II Ongoing, 2000 estimated, Dec. 2021 (bit.ly/2Gy8mhS)
restarted with 1,950
after pause HIV-uninfected
in adults and 50
September people living with
HIV
UK Phase II/III Ongoing, 12,330 estimated, Aug. 2021 (bit.ly/34EOHVj)
restarted with participants
after pause aged 5 years and
in older
September
U.S. Phase III On hold, 30,000 estimated, Oct. 2022 (bit.ly/30O4XCl)
paused in with participants
September aged 18 years and
older
DATA AND REGULATORY TIMELINE
* The lead developer said in July the vaccine could be rolled out by year-end,
but
there has been some uncertainty over the timeline since trials were
paused.
* Experts have predicted a safe and effective vaccine could take 12-18 months to
develop.
* A scientist leading the studies in August said data could be given to
regulators this
year.
* Data from early-stage trials was published in The Lancet medical journal in
July.
* Data from late-stage studies was expected around September, but is now
anticipated to
come in the next few weeks.
* Delivery of the first doses was expected between September and October to
Americans
and Britons, as per the deals signed by AstraZeneca.
REGULATORY REVIEWS
(Most recent first)
REGION/REGULATOR SUBMISSION/R STATUS FORMAL FURTHER
EVIEW APPLICATION
Canada/Health Rolling Launched in Oct Not submitted
Canada submission
Europe/European Rolling Launched in Oct Not submitted
Medicines Agency review
TARGET DOSES/GLOBAL CAPACITY
* More than 3 billion doses.
TIE-UPS
* AstraZeneca has already signed more than a dozen deals to supply the vaccine
and a
similar number of manufacturing agreements. It has also joined with IQVIA to
speed up testing.
* AstraZeneca has been granted protection from future liability claims related to
the
vaccine by most of the countries with which it has struck supply agreements, a senior
executive told Reuters in July.
MANUFACTURING DEALS
(Most recent first)
FIRM BASED IN DEAL VALUE FOR FURTHER
Siam Thailand Undisclosed Manufacture and
Bioscience, supply the vaccine
SCG in Thailand and
other nations in
southeast Asia
Albany U.S. Undisclosed Produce millions of
Molecular doses through
Research sterile finishing
services at its
manufacturing plant
in Albuquerque, New
Mexico
Oxford UK 15 million Unknown doses for
Biomedica pounds to large-scale
reserve commercial
manufacturi manufacture under
ng expanded deal
capacity,
further 35
million
pounds plus
costs
payable in
certain
situations
Catalent U.S. Undisclosed Making the drug
substance used in
the vaccine at its
Maryland facility.
AZ's second deal
with firm
Foundation Mexico Undisclosed Latin American
of Mexican supply with
billionaire Argentina, excluding
Carlos Slim Brazil, could reach
250 million
mAbxience of Argentina Undisclosed Initially producing
the INSUD 150 million doses
Group for Latin America,
excluding Brazil
Kangtai Bio China Undisclosed Annual production
capacity of at least
100 million doses
this year, and at
least 200 million
doses by end-2021
Emergent U.S. $174 Undisclosed doses in
BioSolutions million second deal with AZ
SK South Korea Undisclosed Undiluted solutions
Bioscience of the vaccine until
early 2021
R-Pharm Russia Undisclosed Unknown doses
Daiichi Japan Undisclosed Unknown doses
Sankyo Fundação Brazil $127 About 30 million
Osvaldo Cruz million doses
(Fiocruz)
Symbiosis Scotland Undisclosed Clinical trial
Pharmaceutic supply
al
Cobra U.S. Undisclosed One million doses
Biosciences per month
Catalent U.S. Undisclosed Vial filling and
packaging capacity
at its manufacturing
facility in Anagni,
Italy
Emergent U.S. $87 million 300 million doses
BioSolutions Serum India Undisclosed One billion doses
Institute of for low and
India middle-income
countries, with 400
million before
end-2020
Oxford UK Undisclosed Manufacturing
Biomedica unknown number of
doses
SUPPLY DEALS
(Most recent first)
REGION/GROUP DOSES FUNDING DELIVERIES FURTHER
Switzerland 5.3 million Undisclosed Unknown
Indonesia 100 million Undisclosed First batch
expected to be
available by first
half of 2021
Thailand Unknown Undisclosed First batch
expected to be
available in
mid-2021
Canada Up to 20 million Undisclosed Unknown
doses
Australia "Enough" for Undisclosed Unknown
population of 25
million, free of
cost
European 300 million, with 750 million By end-2020
Union option of euros for 300
additional 100 million doses
million
Latin Initially produce Estimated at First half 2021
America, 150 million doses, $600 million
excluding and eventually for the first
Brazil make at least 400 150 million
million doses
Japan 120 million doses Undisclosed 30 million doses
by March 2021
China Aims for annual Undisclosed By end-2020
production
capacity of at
least 100 million
doses this year,
and at least 200
million doses by
the end of next
year
South Korea Unknown Undisclosed Unknown
Russia Unknown Undisclosed Unknown
Israel Unknown Undisclosed Unknown
Brazil Initially receive $356 million Unknown
100 million doses
Serum One billion, Undisclosed 400 million before
Institute of unspecified number end-2020
India of doses will go
to India
Epidemic 300 million $750 million, Some before end-
response with $383 from 2020
group CEPI CEPI
and Vaccine
alliance
GAVI
United 300 million $1.2 billion By Oct
States
United 100 million 84 million By Sept/Oct
Kingdom pounds
(Sources: Reuters reporting, press releases, clinical trial registers, World
Health Organisation)
($1 = 0.8850 euros)
($1 = 0.8156 pounds)
($1 = 5.6107 reais)
(Reporting by Pushkala Aripaka and Aakash Jagadeesh Babu in Bengaluru; Editing by
Jan Harvey, Mark Potter, Louise Heavens, Alexander Smith and Kirsten Donovan)
我们的标准: 汤森路透“信任原则”